Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674473 | 1.00 | SLC29A1 (0.43) | SLC29A1TYMPPOLBABCG2PRMT6 | |
| SCHEMBL30549354 | 1.00 | SLC29A1 (0.43) | SLC29A1TYMPPOLBABCG2PRMT6 | |
| SCHEMBL21577261 | 0.94 | TYMP (0.46) | TYMPPOLBPRMT6P2RY12 | |
| SCHEMBL22034280 | 0.91 | POLB (0.43) | SLC29A1TYMPPOLBABCG2 | |
| SCHEMBL22034276 | 0.91 | POLB (0.43) | SLC29A1TYMPPOLBABCG2 | |
| SCHEMBL3822659 | 0.87 | TYMP (0.47) | TYMPPRMT6P2RY12 | |
| SCHEMBL532593 | 0.87 | TYMP (0.46) | TYMPPOLB | |
| SCHEMBL25505308 | 0.86 | SLC29A1 (0.49) | SLC29A1POLBPRMT6P2RY12 | |
| SCHEMBL25386259 | 0.86 | SLC29A1 (0.42) | SLC29A1TYMPP2RY12 | |
| SCHEMBL14049947 | 0.86 | TYMP (0.44) | TYMPPRMT6P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4013428-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220064636-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3861118-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2020072991-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064636-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | NOP2, NOP58, PHAX | SLC29A1 314/4885TYMP 179/4885POLB 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.